BACKGROUND:Lipoatrophy is prevalent on thymidine nucleoside reverse transcriptase inhibitors (tNRTIs). A pilot trial showed that uridine (NucleomaxX) increased limb fat. METHODS:A5229 was a multicenter trial in which HIV-infected individuals with lipoatrophy on tNRTI regimens were randomized to NucleomaxX or placebo. Primary endpoint was change in limb fat from baseline to week 48. The study was powered to detect 400-g difference between arms at week 48. A stratified Wilcoxon rank-sum test was used to assess between-arm differences. RESULTS: The 165 participants were 91% men, 62% white; median age 49 years, CD4 cell count 506 cells/μl, and limb fat 3037 g; 81% had HIV-1 RNA 50 copies/ml or less; 76% were onzidovudine (ZDV). Baseline characteristics were similar between groups. Only 59% completed 48 weeks of treatment; however, only three participants (one on uridine) discontinued due to toxicity (diarrhea). In intent to treat, there was no difference for changes in limb fat between treatments at week 24 or week 48. On as-treated analysis, uridine resulted in an increase in %limb fat vs. placebo (3.4 vs. -0.8%, P = 0.01) at week 24 but not at week 48 (1.8 vs. 3.8%, P = 0.93). Similar results were seen when limiting the analysis to patients with at least 80% adherence. The results were not related to severity of lipoatrophy or type of tNRTI. No changes were found in facial anthropometrics, fasting lipids, trunk fat, CD4 cell count, or HIV RNA. CONCLUSIONS: We found a modest transient improvement in limb fat after 24 weeks of uridine. The lack of sustained efficacy at week 48 was not due to changes in adherence or reduction in sample size. Uridine was well tolerated and did not impair virologic control.
RCT Entities:
BACKGROUND: Lipoatrophy is prevalent on thymidinenucleoside reverse transcriptase inhibitors (tNRTIs). A pilot trial showed that uridine (NucleomaxX) increased limb fat. METHODS: A5229 was a multicenter trial in which HIV-infected individuals with lipoatrophy on tNRTI regimens were randomized to NucleomaxX or placebo. Primary endpoint was change in limb fat from baseline to week 48. The study was powered to detect 400-g difference between arms at week 48. A stratified Wilcoxon rank-sum test was used to assess between-arm differences. RESULTS: The 165 participants were 91% men, 62% white; median age 49 years, CD4 cell count 506 cells/μl, and limb fat 3037 g; 81% had HIV-1 RNA 50 copies/ml or less; 76% were on zidovudine (ZDV). Baseline characteristics were similar between groups. Only 59% completed 48 weeks of treatment; however, only three participants (one on uridine) discontinued due to toxicity (diarrhea). In intent to treat, there was no difference for changes in limb fat between treatments at week 24 or week 48. On as-treated analysis, uridine resulted in an increase in %limb fat vs. placebo (3.4 vs. -0.8%, P = 0.01) at week 24 but not at week 48 (1.8 vs. 3.8%, P = 0.93). Similar results were seen when limiting the analysis to patients with at least 80% adherence. The results were not related to severity of lipoatrophy or type of tNRTI. No changes were found in facial anthropometrics, fasting lipids, trunk fat, CD4 cell count, or HIV RNA. CONCLUSIONS: We found a modest transient improvement in limb fat after 24 weeks of uridine. The lack of sustained efficacy at week 48 was not due to changes in adherence or reduction in sample size. Uridine was well tolerated and did not impair virologic control.
Authors: David Nolan; Emma Hammond; Annalise Martin; Louise Taylor; Susan Herrmann; Elizabeth McKinnon; Cecily Metcalf; Bruce Latham; Simon Mallal Journal: AIDS Date: 2003-06-13 Impact factor: 4.177
Authors: Graeme J Moyle; Caroline A Sabin; Jonathan Cartledge; Margaret Johnson; Edmund Wilkins; Duncan Churchill; Philip Hay; Ade Fakoya; Maurice Murphy; George Scullard; Clifford Leen; Geraldine Reilly Journal: AIDS Date: 2006-10-24 Impact factor: 4.177
Authors: Grace A McComsey; Douglas J Ward; Siegrid M Hessenthaler; Michael G Sension; Peter Shalit; J Tyler Lonergan; Robin L Fisher; Vanessa C Williams; Jaime E Hernandez Journal: Clin Infect Dis Date: 2003-12-18 Impact factor: 9.079
Authors: Pere Domingo; Javier Torres-Torronteras; Virginia Pomar; Marta Giralt; Joan Carles Domingo; Maria Del Mar Gutierrez; José M Gallego-Escuredo; Maria Gracia Mateo; Pedro Cano-Soldado; Irene Fernandez; Marçal Pastor-Anglada; Francesc Vidal; Francesc Villarroya; Antoni Andreu; Ramon Marti Journal: PLoS One Date: 2010-11-15 Impact factor: 3.240
Authors: S Selvaraj; M Ghebremichael; M Li; Y Foli; A Langs-Barlow; A Ogbuagu; L Barakat; E Tubridy; R Edifor; W Lam; Y-C Cheng; E Paintsil Journal: Clin Pharmacol Ther Date: 2014-03-17 Impact factor: 6.875